Autobio Diagnostics

Launch date

1998

Employees

Market cap

Enterprise valuation

AUD4.7b (Public information from Sep 2024)

China (HQ)

http://www.autobio.com.cn/en/

https://www.linkedin.com/company/autobio-diagnostics/https://apps.apple.com/app/id1415573886

Revenues, earnings & profits over time

CNY	2020	2021	2022	2023	2024	2025	2026
Revenues	3.0b	3.8b	4.4b	4.4b	4.9b	5.8b	6.7b
% growth	11 %	26 %	18 %	-	10 %	18 %	17 %
EBITDA	1.2b	1.5b	1.8b	1.9b	1.9b	2.2b	2.6b
% EBITDA margin	41 %	40 %	41 %	43 %	38 %	38 %	38 %
Profit	748m	974m	1.2b	1.2b	1.4b	1.7b	2.1b
% profit margin	25 %	26 %	26 %	27 %	29 %	30 %	31 %
EV / revenue	22.0x	8.4x	7.9x	7.3x	4.6x	3.8x	3.1x
EV / EBITDA	54.3x	21.3x	19.5x	17.1x	12.0x	9.9x	8.1x
R&D budget	343m	481m	568m	656m	-	-	-
R&D % of revenue	12 %	13 %	13 %	15 %	-	-	-

Date	Investors	Amount	Round
Sep 2016	N/A	N/A	IPO
Total Funding		-

ACQUISITION by Hologic Apr 2021

Shenzhen Meili Nanopore Technology